ArticleCurrent oncology (Toronto, Ont.)2024

Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors.

Pınar Kubilay Tolunay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.